By the end of 2022, the global automated cell biology systems market is anticipated to be worth US$ 14.1 Billion, and it will grow at a CAGR of 9.0% to reach an expected valuation of around US$ 33.5 Billion by the year 2032. Infinite cell line cultures dominate the worldwide market in 2021, with a share of around 76.2%, according to a recent analysis by Future Market Insights.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 14.1 Billion |
| Market Value 2032 | US$ 33.5 Billion |
| CAGR 2022 to 2032 | 9.0% |
| Market Share of Top 5 Countries | 62.3% |
| Key Market Players | Thermo Fisher Scientific, Corning Incorporated, Merck KGaA, Lonza, Sartorius AG, Hitachi. Ltd, Nanoentek, ChemoMetec, Danaher Corporation, Agilent Technologies, Perkin Elmer (Nexcelom Bioscience LLC.), F. Hoffmann-La Roche AG, SHIMADZU CORPORATION, Bio-Rad Laboratories, Miltenyi Biotec, Sinfonia Technology, SHIBUYA CORPORATION, Advanced Instruments, Cell Culture Company, LLC, BD, and Hamilton Company |
Compared to the widespread methods utilized in the second half of the twentieth century, modern cell cultivation techniques are not significantly different. Despite the fact that these techniques made it possible to comprehend a variety of biological processes and that they served as determining factors for applications like drug testing and tissue regeneration, they had a number of inherent drawbacks. In actuality, conventional cell culture systems necessitate numerous and intricate manual handling techniques, which restricts the consistency of the cultivation in terms of cell yield and activity.
Additionally, long-term cell maintenance is costly, time-consuming, and demands a lot of reagents, test samples, and work. By reducing the number of operator interventions, the shift to user-friendly automated devices would favor standardizing the cultivation process, cutting production costs, and shortening the time required for cell culture preparation, thus promoting market growth for automated cell biology systems.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market value for automated cell biology systems was approximately 65.8% of the overall ~US$ 19.9 Billion global bioprocess technology market in 2021.
The sale of automated cell biology systems expanded at a CAGR of 6.6% from 2015 to 2021.
Technologies like microfluidics and lab-on-a-chip represent a strategic approach to support the shift to user-friendly automated equipment. By using microculture systems in place of conventional Petri plates and flasks for cellular tests, researchers have been able to minimize the number of reagents used while still achieving high-throughput cell generation and culture in a controlled setting.
The development of tissue engineering aims to increase the possibility of replacing tissue development for regenerating or restoring organ and tissue function. Tissue engineering technology has advanced significantly in recent years, and it is now widely used in domains other than medicine, such as organs-on-a-chip, bioelectronic devices, cultured meats, and so on.
Cell culture is the primary method used for tissue engineering manufacturing. Therefore, it is crucial for tissue engineering research to maintain high standards for cell culture settings.
Modern uses of analytical system automation include clinical, pharmacological, and biomedical environments. The automatic system has played a significant role in both qualitative and quantitative analysis. Optically driven, electrochemical, and mass spectroscopic approaches have all been used as analytical techniques. Robotic automation lowers the cost of analysis while providing high precision and high system throughput.
Numerous lab-on-chip advancements have been made for cell culture and certain other biomedical applications. A cell culture device indicates the viability of the cells, nutrient consumption, nutrient output in the fermentation process, and pharmacological effect.
Because of the aforementioned factors, it is anticipated that from 2022 to 2032, the global automated cell biology systems market will expand at a CAGR of 9.0%.
As automated cell culture, on-chip is widely acknowledged as a benchmark parameter in existing microfluidic systems for cell biology, and a plethora of studies have been documented in the literature. At the research laboratory level, the minimization and downsizing of additional peripheral equipment are considered a fundamental necessity for the utilization of automated devices in cell culture, coupled with the need for systems that are ready-to-use in a plug-and-play mode.
Currently, the use of micro-devices for fluidic control is limited to the use of relatively complicated, specialized, and bulky external equipment and macro-to-micro interface systems, necessitating the ongoing assistance of human operators to manage fluid flow in an unstandardized and manual manner.
The systematic application of a suitably integrated control system for accurate fluid handling in a remote control framework will significantly improve the usability and readout dependability of micro-bioreactors. This is crucial in automating cell culture techniques, reducing human involvement, and significantly lowering the number of connection tubes, intake and output ports, and bulky external equipment.
The adoption of such control systems is gaining traction, owing to the above-mentioned factors, and this is set to pose lucrative opportunities for growth within the global automated cell biology systems market during the forecasted years.
Principal Consultant
Cell-based therapies have the ability to provide a successful treatment for medical disorders that are presently incurable. Their widespread commercialization has been put at risk by constraints such as scaling up and automating labor-intensive research discoveries, high production costs, and batch variance in large-scale automated manufacturing.
Additionally, even though many cell culture labs employ automated tools to do away with manual duties like handling plates, highly-trained lab staff are still required to spend hours every day maintaining these devices. As a result, the majority of benchtop automation has limitations in terms of scaling in cell culture facilities.
Furthermore, the utilization of mammalian cell culture is quickly expanding. Even though the fundamental processes for sustaining cells are quite repeatable, the majority of cell culture operations are still done by hand.
Personnel is required to perform repetitive tasks for hours on end each day, and frequently they must come in after regular working hours to cater to the cells or modify their biology to accommodate the workload. Both the workflow's throughput and its ability to be tracked are limited by this dependence on manual steps.
With the above-mentioned factors, the market for automated cell biology systems experiences a restraint in growth.
With a market share of 89.8% in all of North America in 2021, the USA presently dominates the region and is expected to sustain this growth throughout the forecast period.
The increasing expenditure on Research and Development in the area can be attributed to the market's expansion. Additionally, the expansion of pharmaceutical firms and manufacturers in the area together with rising public awareness of stem cell therapy is anticipated to significantly contribute to the market's expansion. Additionally, it is predicted that the rising number of bone marrow and cord blood transplants across the region will favorably influence market growth.
China represents roughly 64.9% of the East Asia market in 2021, with growth at a lucrative CAGR of 13.7% throughout the forecast period. China has a significant demand for automation, according to the International Federation of Robotics (IFR). According to sales volume, China was one of the top five markets for industrial robots in 2015.
The China Robot Industry Alliance estimates that Chinese robot suppliers sold about 20,400 units in 2015, increasing their share of the global market from 25% to 29% from 2013 until 2015. With the growing wave in automation, as well as its adoption, China is posed to be a highly lucrative market for automated cell biology systems over the forecast period.
During the forecast years, Germany is projected to grow at a CAGR of nearly 7.2% in the global automated cell biology systems market. The European Medicinal Agency (EMA) granted the CliniMACS Prodigy platform approval for the commercial manufacturing process in 2018 for the customization of protocols, which is accomplished through modularity and flexible programming, allowing its use for a number of different cell types, including the development of CAR-T cells, macrophages, virus-specific T-cells, and dendritic cells. With the manufacturing of such capable platforms, Germany is set to aid with the growth of the overall market during the projected period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Automated cell counters (single function) are the leading segment as a product, hold approximately 34.6% market share in 2021, and are expected to present high growth at a CAGR of 8.1% throughout the forecast period. The benefit of using an automated cell counter is that it largely eliminates human bias from the cell counting process. They can count more cells and are frequently faster than manually counting, which improves statistical accuracy. Automated cell counters are also employed in research and clinical labs. They can be used on urine and blood samples to count the different cell types present or to evaluate the viability of a cultivated cell line for investigation.
Infinite cell line cultures hold a global market share of around 76.2%, in 2021. Infinite cell line cultures are more robust and convenient to work with than primary cells since they can reproduce indefinitely. Infinite cell line cultures are also convenient for researchers because they are less expensive, easier to use, and able to survive more stages than primary cells. Because cell lines have a limitless supply of material and are simple to alter and grow, they are preferred for multiple screenings.
Drug development holds a share of around 35.4% in 2021, and this segment is expected to display gradual growth over the forecast period. New scientific developments in basic research, drug development, drug discovery, and customized medicine applications are being driven by 3D cell cultures. To understand the full potential of the technology, researchers can operate more efficiently with complex reagents and precious cells with the aid of high throughput, automated liquid handling solutions.
Biopharmaceutical companies hold the highest market share value of 27.4% during the year 2021. Growing drug development activities propelled by the rising demand for personalized medicine will propel this segment in terms of growth during the projected years. With the standardization of laboratory protocols, as well as the utilization of automated systems for process control technologies during the production process, this segment gains a higher share among the rest of the end users within the global market.
Key players in the market present novel solutions for the lab automation processes for cell biology systems. Moreover, with increasing approvals from the regulatory authorities for software-based total lab automation systems, the key players are presented with an opportunistic outlook for growth during the forecast period.
Similarly, recent developments related to companies manufacturing automated cell biology systems have been tracked by the team at Future Market Insights, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2022 to 2032 |
| Historical Data Available for | 2015 to 2021 |
| Market Analysis | US$ Billion for Value |
| Key Regions Covered | North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, United Kingdom, Germany, Italy, Russia, Spain, France, BENELUX, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC Countries, North Africa, and South Africa |
| Key Market Segments Covered | Product, Cell Culture, Application, End User, and Region |
| Key Companies Profiled |
|
| Pricing | Available upon Request |
The global automated cell biology systems market stands at US$ 14.1 Billion in 2022 and is set to expand 2.4X over the next ten years.
The automated cell biology systems market is expected to reach US$ 33.5 Billion by end of 2032 at a CAGR of 9.0%.
The growing geriatric population, the rising burden of chronic and infectious diseases, and rising Research and Development on novel biopharmaceuticals are some of the key trends in this market.
By region, North America holds the highest market share of around 37.4% by value, in 2021, in the global automated cell biology systems market.
Europe is projected to grow with a CAGR of 7.5% during the forecast period.
The USA, Germany, India, China, and the United Kingdom are the top five countries, which are expected to drive demand in the automated cell biology systems market.
Thermo Fisher Scientific, Corning Incorporated, Merck KGaA, Lonza, Sartorius AG, Hitachi. Ltd, Nanoentek, ChemoMetec, Danaher Corporation, Agilent Technologies, Perkin Elmer (Nexcelom Bioscience LLC.), F. Hoffmann-La Roche AG, SHIMADZU CORPORATION, Bio-Rad Laboratories, Miltenyi Biotec, Sinfonia Technology, SHIBUYA CORPORATION, Advanced Instruments, Cell Culture Company, LLC, BD, and Hamilton Company, are some of the key players in the automated cell biology systems industry.
From 2015 to 2021, the market for automated cell biology systems expanded at the rate of 6.6% CAGR.
The automated cell biology systems market in South Asia is expected to grow at 12.3% CAGR during the forecast period.
East Asia is set to present lucrative growth at a CAGR of 13.1% during the forecasted years.
The automated cell biology systems market in South Asia is expected to grow at 12.3% CAGR during the forecast period.
East Asia is set to present lucrative growth at a CAGR of 13.1% during the forecasted years.
1. Executive Summary | Automated Cell Biology Systems Market
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Innovation / Development Trends
4. Key Success Factors
4.1. Product Adoption Analysis
4.2. Regulatory Landscape
4.3. Reimbursement Scenario
4.4. PESTEL Analysis
4.5. Porter’s Analysis
4.6. Value Chain Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Outlook
5.1.3. Global Market Overview
5.2. Forecast Factors - Relevance & Impact
5.2.1. Increasing Prevalence of Chronic and Infectious Diseases
5.2.2. Growing Elderly Population
5.2.3. Growing Efforts on Stem Cell Research
5.2.4. Increasing Demand for Gene Therapies
5.2.5. Rising Biopharmaceutical Production
5.2.6. Growing Investments in R&D
5.2.7. Rising Adoption of Automated Systems for Bulk Manufacturing
5.2.8. Increasing Focus on New Drug Discovery and Development
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
6.1. COVID-19 and Impact Analysis
6.1.1. By Product
6.1.2. By Application
6.1.3. By Cell Culture
6.1.4. By End User
6.1.5. By Country
6.2. 2021 Market Scenario
7. Global Market Volume (Units) Analysis 2015 to 2021 and Forecast, 2022 to 2032
7.1. Historical Market Volume (Units) Analysis, 2015 to 2021
7.2. Current and Future Market Volume (Units) Projections, 2022 to 2032
7.2.1. Y-o-Y Growth Trend Analysis
8. Global Market - Pricing Analysis
8.1. Regional Pricing Analysis By Product
8.2. Pricing Break-up
8.2.1. Manufacturer-Level Pricing
8.2.2. Distributor Level Pricing
8.3. Global Average Pricing Analysis Benchmark
8.4. Pricing Assumptions
9. Global Market Demand (in Value or Size in US$ Million) Analysis 2015 to 2021 and Forecast, 2022 to 2032
9.1. Historical Market Value (US$ Million) Analysis, 2015 to 2021
9.2. Current and Future Market Value (US$ Million) Projections, 2022 to 2032
9.2.1. Y-o-Y Growth Trend Analysis
9.2.2. Absolute $ Opportunity Analysis
10. Global Market Analysis, By Product
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Product, 2015 to 2021
10.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Product, 2022 to 2032
10.3.1. Cell Culture Process Automatization Instrument or Robot (Multiple Function)
10.3.2. Automated Bioreactor (Single or Multiple Function)
10.3.3. Automated Cell Culture Media Exchange System (Single Function)
10.3.4. Automated Culture Media Analyzer (Single Function)
10.3.5. Automated Cell Wash-and-Concentrate System (Single Function)
10.3.6. Automated Cell Counter (Single Function)
10.3.7. Automated Fill and Finish System (Single Function)
10.3.8. Automated Cell Storage Equipment (Single Function)
10.3.9. Management Software
10.4. Market Attractiveness Analysis By Product
11. Global Market Analysis, By Cell Culture
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Million) Analysis By Cell Culture, 2015 to 2021
11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Cell Culture, 2022 to 2032
11.3.1. Finite Cell Line Cultures
11.3.2. Infinite Cell Line Cultures
11.4. Market Attractiveness Analysis By Cell Culture
12. Global Market Analysis, By Application
12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Million) Analysis, By Application, 2015 to 2021
12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Application, 2022 to 2032
12.3.1. Cell Therapy
12.3.2. Drug Development
12.3.3. Stem Cell Research
12.3.4. Regenerative Medicine
12.4. Market Attractiveness Analysis By Application
13. Global Market Analysis, By End User
13.1. Introduction / Key Findings
13.2. Historical Market Size (US$ Million) Analysis, By End User, 2015 to 2021
13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By End User, 2022 to 2032
13.3.1. Mega Pharmaceutical companies
13.3.2. Biopharmaceutical companies
13.3.3. CDMOs/CMOs
13.3.4. Research organizations
13.3.5. Academic institutes
13.4. Market Attractiveness Analysis By End User
14. Global Market Analysis, By Region
14.1. Introduction
14.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Region, 2015 to 2021
14.3. Current and Future Market Value (US$ Million) and Volume (Units) Analysis and Forecast, 2022 to 2032
14.3.1. North America
14.3.2. Latin America
14.3.3. Europe
14.3.4. East Asia
14.3.5. South Asia
14.3.6. Oceania
14.3.7. Middle East and Africa (MEA)
14.4. Market Attractiveness Analysis By Region
15. North America Market Analysis
15.1. Introduction
15.2. Historical Market Size (US$ Million) Trend and Volume (Units) Analysis By Market Taxonomy, 2015 to 2021
15.3. Current and Future Market Value (US$ Million) and Volume (Units) Analysis and Forecast, 2022 to 2032
15.3.1. By Country
15.3.1.1. USA
15.3.1.2. Canada
15.3.2. By Product
15.3.3. By Application
15.3.4. By Cell Culture
15.3.5. By End User
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Product
15.4.3. By Cell Culture
15.4.4. By Application
15.4.5. By End User
15.5. Market Trends
15.6. Drivers and Restraints - Impact Analysis
15.7. Country-Level Analysis & Forecast
15.7.1. USA Market Analysis
15.7.1.1. Introduction
15.7.1.2. Market Analysis and Forecast by Market Taxonomy
15.7.1.2.1. By Product
15.7.1.2.2. By Cell Culture
15.7.1.2.3. By Application
15.7.1.2.4. By End User
15.7.2. Canada Market Analysis
15.7.2.1. Introduction
15.7.2.2. Market Analysis and Forecast by Market Taxonomy
15.7.2.2.1. By Product
15.7.2.2.2. By Cell Culture
15.7.2.2.3. By Application
15.7.2.2.4. By End User
16. Latin America Market Analysis
16.1. Introduction
16.2. Historical Market Size (US$ Million) Trend and Volume (Units) Analysis By Market Taxonomy, 2015 to 2021
16.3. Current and Future Market Value (US$ Million) and Volume (Units) Analysis and Forecast, 2022 to 2032
16.3.1. By Country
16.3.1.1. Mexico
16.3.1.2. Brazil
16.3.1.3. Argentina
16.3.1.4. Rest of Latin America
16.3.2. By Product
16.3.3. By Cell Culture
16.3.4. By Application
16.3.5. By End User
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Product
16.4.3. By Cell Culture
16.4.4. By Application
16.4.5. By End User
16.5. Market Trends
16.6. Drivers and Restraints - Impact Analysis
16.7. Country-Level Analysis & Forecast
16.7.1. Mexico Market Analysis
16.7.1.1. Introduction
16.7.1.2. Market Analysis and Forecast by Market Taxonomy
16.7.1.2.1. By Product
16.7.1.2.2. By Cell Culture
16.7.1.2.3. By Application
16.7.1.2.4. By End User
16.7.2. Brazil Market Analysis
16.7.2.1. Introduction
16.7.2.2. Market Analysis and Forecast by Market Taxonomy
16.7.2.2.1. By Product
16.7.2.2.2. By Cell Culture
16.7.2.2.3. By Application
16.7.2.2.4. By End User
16.7.3. Argentina Market Analysis
16.7.3.1. Introduction
16.7.3.2. Market Analysis and Forecast by Market Taxonomy
16.7.3.2.1. By Product
16.7.3.2.2. By Cell Culture
16.7.3.2.3. By Application
16.7.3.2.4. By End User
17. Europe Market Analysis
17.1. Introduction
17.2. Historical Market Size (US$ Million) Trend and Volume (Units) Analysis By Market Taxonomy, 2015 to 2021
17.3. Current and Future Market Value (US$ Million) and Volume (Units) Analysis and Forecast, 2022 to 2032
17.3.1. By Country
17.3.1.1. Germany
17.3.1.2. Italy
17.3.1.3. France
17.3.1.4. United Kingdom
17.3.1.5. Spain
17.3.1.6. BENELUX
17.3.1.7. Russia
17.3.1.8. Rest of Europe
17.3.2. By Product
17.3.3. By Cell Culture
17.3.4. By Application
17.3.5. By End User
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Product
17.4.3. By Cell Culture
17.4.4. By Application
17.4.5. By End User
17.5. Market Trends
17.6. Drivers and Restraints - Impact Analysis
17.7. Country-Level Analysis & Forecast
17.7.1. Germany Market Analysis
17.7.1.1. Introduction
17.7.1.2. Market Analysis and Forecast by Market Taxonomy
17.7.1.2.1. By Product
17.7.1.2.2. By Cell Culture
17.7.1.2.3. By Application
17.7.1.2.4. By End User
17.7.2. Italy Market Analysis
17.7.2.1. Introduction
17.7.2.2. Market Analysis and Forecast by Market Taxonomy
17.7.2.2.1. By Product
17.7.2.2.2. By Cell Culture
17.7.2.2.3. By Application
17.7.2.2.4. By End User
17.7.3. France Market Analysis
17.7.3.1. Introduction
17.7.3.2. Market Analysis and Forecast by Market Taxonomy
17.7.3.2.1. By Product
17.7.3.2.2. By Cell Culture
17.7.3.2.3. By Application
17.7.3.2.4. By End User
17.7.4. United Kingdom Market Analysis
17.7.4.1. Introduction
17.7.4.2. Market Analysis and Forecast by Market Taxonomy
17.7.4.2.1. By Product
17.7.4.2.2. By Cell Culture
17.7.4.2.3. By Application
17.7.4.2.4. By End User
17.7.5. Spain Market Analysis
17.7.5.1. Introduction
17.7.5.2. Market Analysis and Forecast by Market Taxonomy
17.7.5.2.1. By Product
17.7.5.2.2. By Cell Culture
17.7.5.2.3. By Application
17.7.5.2.4. By End User
17.7.6. BENELUX Market Analysis
17.7.6.1. Introduction
17.7.6.2. Market Analysis and Forecast by Market Taxonomy
17.7.6.2.1. By Product
17.7.6.2.2. By Cell Culture
17.7.6.2.3. By Application
17.7.6.2.4. By End User
17.7.7. Russia Market Analysis
17.7.7.1. Introduction
17.7.7.2. Market Analysis and Forecast by Market Taxonomy
17.7.7.2.1. By Product
17.7.7.2.2. By Cell Culture
17.7.7.2.3. By Application
17.7.7.2.4. By End User
18. East Asia Market Analysis
18.1. Introduction
18.2. Historical Market Size (US$ Million) Trend and Volume (Units) Analysis By Market Taxonomy, 2015 to 2021
18.3. Current and Future Market Value (US$ Million) and Volume (Units) Analysis and Forecast, 2022 to 2032
18.3.1. By Country
18.3.1.1. China
18.3.1.2. Japan
18.3.1.3. South Korea
18.3.2. By Product
18.3.3. By Cell Culture
18.3.4. By Application
18.3.5. By End User
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Cell Culture
18.4.3. By Product
18.4.4. By Application
18.4.5. By End User
18.5. Market Trends
18.6. Drivers and Restraints - Impact Analysis
18.7. Country-Level Analysis & Forecast
18.7.1. China Market Analysis
18.7.1.1. Introduction
18.7.1.2. Market Analysis and Forecast by Market Taxonomy
18.7.1.2.1. By Product
18.7.1.2.2. By Cell Culture
18.7.1.2.3. By Application
18.7.1.2.4. By End User
18.7.2. Japan Market Analysis
18.7.2.1. Introduction
18.7.2.2. Market Analysis and Forecast by Market Taxonomy
18.7.2.2.1. By Product
18.7.2.2.2. By Cell Culture
18.7.2.2.3. By Application
18.7.2.2.4. By End User
18.7.3. South Korea Market Analysis
18.7.3.1. Introduction
18.7.3.2. Market Analysis and Forecast by Market Taxonomy
18.7.3.2.1. By Product
18.7.3.2.2. By Cell Culture
18.7.3.2.3. By Application
18.7.3.2.4. By End User
19. South Asia Market Analysis
19.1. Introduction
19.2. Historical Market Size (US$ Million) Trend and Volume (Units) Analysis By Market Taxonomy, 2015 to 2021
19.3. Current and Future Market Value (US$ Million) and Volume (Units) Analysis and Forecast, 2022 to 2032
19.3.1. By Country
19.3.1.1. India
19.3.1.2. Indonesia
19.3.1.3. Malaysia
19.3.1.4. Thailand
19.3.1.5. Rest of South Asia
19.3.2. By Product
19.3.3. By Cell Culture
19.3.4. By Application
19.3.5. By End User
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Cell Culture
19.4.3. By Product
19.4.4. By Application
19.4.5. By End User
19.5. Market Trends
19.6. Drivers and Restraints - Impact Analysis
19.7. Country-Level Analysis & Forecast
19.7.1. India Market Analysis
19.7.1.1. Introduction
19.7.1.2. Market Analysis and Forecast by Market Taxonomy
19.7.1.2.1. By Product
19.7.1.2.2. By Cell Culture
19.7.1.2.3. By Application
19.7.1.2.4. By End User
19.7.2. Indonesia Market Analysis
19.7.2.1. Introduction
19.7.2.2. Market Analysis and Forecast by Market Taxonomy
19.7.2.2.1. By Product
19.7.2.2.2. By Cell Culture
19.7.2.2.3. By Application
19.7.2.2.4. By End User
19.7.3. Malaysia Market Analysis
19.7.3.1. Introduction
19.7.3.2. Market Analysis and Forecast by Market Taxonomy
19.7.3.2.1. By Product
19.7.3.2.2. By Cell Culture
19.7.3.2.3. By Application
19.7.3.2.4. By End User
19.7.4. Thailand Market Analysis
19.7.4.1. Introduction
19.7.4.2. Market Analysis and Forecast by Market Taxonomy
19.7.4.2.1. By Product
19.7.4.2.2. By Cell Culture
19.7.4.2.3. By Application
19.7.4.2.4. By End User
20. Oceania Market Analysis
20.1. Introduction
20.2. Historical Market Size (US$ Million) Trend and Volume (Units) Analysis By Market Taxonomy, 2015 to 2021
20.3. Current and Future Market Value (US$ Million) and Volume (Units) Analysis and Forecast, 2022 to 2032
20.3.1. By Country
20.3.1.1. Australia
20.3.1.2. New Zealand
20.3.2. By Product
20.3.3. By Cell Culture
20.3.4. By Application
20.3.5. By End User
20.4. Market Attractiveness Analysis
20.4.1. By Country
20.4.2. By Product
20.4.3. By Cell Culture
20.4.4. By Application
20.4.5. By End User
20.5. Key Market Participants - Intensity Mapping
20.6. Drivers and Restraints - Impact Analysis
20.7. Country-Level Analysis & Forecast
20.7.1. Australia Market Analysis
20.7.1.1. Introduction
20.7.1.2. Market Analysis and Forecast by Market Taxonomy
20.7.1.2.1. By Product
20.7.1.2.2. By Cell Culture
20.7.1.2.3. By Application
20.7.1.2.4. By End User
20.7.2. New Zealand Market Analysis
20.7.2.1. Introduction
20.7.2.2. Market Analysis and Forecast by Market Taxonomy
20.7.2.2.1. By Product
20.7.2.2.2. By Cell Culture
20.7.2.2.3. By Application
20.7.2.2.4. By End User
21. Middle East and Africa (MEA) Market Analysis
21.1. Introduction
21.2. Historical Market Size (US$ Million) Trend and Volume (Units) Analysis By Market Taxonomy, 2015 to 2021
21.3. Current and Future Market Value (US$ Million) and Volume (Units) Analysis and Forecast, 2022 to 2032
21.3.1. By Country
21.3.1.1. GCC Countries
21.3.1.2. Turkey
21.3.1.3. North Africa
21.3.1.4. South Africa
21.3.1.5. Rest of Middle East and Africa
21.3.2. By Product
21.3.3. By Cell Culture
21.3.4. By Application
21.3.5. By End User
21.4. Market Attractiveness Analysis
21.4.1. By Country
21.4.2. By Product
21.4.3. By Cell Culture
21.4.4. By Application
21.4.5. By End User
21.5. Market Trends
21.6. Drivers and Restraints - Impact Analysis
21.7. Country-Level Analysis & Forecast
21.7.1. GCC Countries Market Analysis
21.7.1.1. Introduction
21.7.1.2. Market Analysis and Forecast by Market Taxonomy
21.7.1.2.1. By Product
21.7.1.2.2. By Cell Culture
21.7.1.2.3. By Application
21.7.1.2.4. By End User
21.7.2. Turkey Market Analysis
21.7.2.1. Introduction
21.7.2.2. Market Analysis and Forecast by Market Taxonomy
21.7.2.2.1. By Product
21.7.2.2.2. By Cell Culture
21.7.2.2.3. By Application
21.7.2.2.4. By End User
21.7.3. South Africa Market Analysis
21.7.3.1. Introduction
21.7.3.2. Market Analysis and Forecast by Market Taxonomy
21.7.3.2.1. By Product
21.7.3.2.2. By Cell Culture
21.7.3.2.3. By Application
21.7.3.2.4. By End User
21.7.4. North Africa Market Analysis
21.7.4.1. Introduction
21.7.4.2. Market Analysis and Forecast by Market Taxonomy
21.7.4.2.1. By Product
21.7.4.2.2. By Cell Culture
21.7.4.2.3. By Application
21.7.4.2.4. By End User
22. Market Structure Analysis
22.1. Market Analysis by Tier of Companies
22.2. Market Share Analysis of Top Players
22.3. Market Presence Analysis
23. Competition Analysis
23.1. Competition Dashboard
23.2. Competition Benchmarking
23.3. Competition Deep Dive
23.3.1. Thermo Fisher Scientific
23.3.1.1. Overview
23.3.1.2. Product Portfolio
23.3.1.3. Sales Footprint
23.3.1.4. Key Financials
23.3.1.5. SWOT Analysis
23.3.1.6. Strategy Overview
23.3.1.6.1. Marketing Strategy
23.3.1.6.2. Product Strategy
23.3.1.6.3. Channel Strategy
23.3.2. Corning Incorporated
23.3.2.1. Overview
23.3.2.2. Product Portfolio
23.3.2.3. Sales Footprint
23.3.2.4. Key Financials
23.3.2.5. SWOT Analysis
23.3.2.6. Strategy Overview
23.3.2.6.1. Marketing Strategy
23.3.2.6.2. Product Strategy
23.3.2.6.3. Channel Strategy
23.3.3. Merck KGaA
23.3.3.1. Overview
23.3.3.2. Product Portfolio
23.3.3.3. Sales Footprint
23.3.3.4. Key Financials
23.3.3.5. SWOT Analysis
23.3.3.6. Strategy Overview
23.3.3.6.1. Marketing Strategy
23.3.3.6.2. Product Strategy
23.3.3.6.3. Channel Strategy
23.3.4. Lonza
23.3.4.1. Overview
23.3.4.2. Product Portfolio
23.3.4.3. Sales Footprint
23.3.4.4. Key Financials
23.3.4.5. SWOT Analysis
23.3.4.6. Strategy Overview
23.3.4.6.1. Marketing Strategy
23.3.4.6.2. Product Strategy
23.3.4.6.3. Channel Strategy
23.3.5. Sartorius AG
23.3.5.1. Overview
23.3.5.2. Product Portfolio
23.3.5.3. Sales Footprint
23.3.5.4. Key Financials
23.3.5.5. SWOT Analysis
23.3.5.6. Strategy Overview
23.3.5.6.1. Marketing Strategy
23.3.5.6.2. Product Strategy
23.3.5.6.3. Channel Strategy
23.3.6. Hitachi. Ltd
23.3.6.1. Overview
23.3.6.2. Product Portfolio
23.3.6.3. Sales Footprint
23.3.6.4. Key Financials
23.3.6.5. SWOT Analysis
23.3.6.6. Strategy Overview
23.3.6.6.1. Marketing Strategy
23.3.6.6.2. Product Strategy
23.3.6.6.3. Channel Strategy
23.3.7. Nanoentek
23.3.7.1. Overview
23.3.7.2. Product Portfolio
23.3.7.3. Sales Footprint
23.3.7.4. Key Financials
23.3.7.5. SWOT Analysis
23.3.7.6. Strategy Overview
23.3.7.6.1. Marketing Strategy
23.3.7.6.2. Product Strategy
23.3.7.6.3. Channel Strategy
23.3.8. ChemoMetec
23.3.8.1. Overview
23.3.8.2. Product Portfolio
23.3.8.3. Sales Footprint
23.3.8.4. Key Financials
23.3.8.5. SWOT Analysis
23.3.8.6. Strategy Overview
23.3.8.6.1. Marketing Strategy
23.3.8.6.2. Product Strategy
23.3.8.6.3. Channel Strategy
23.3.9. Danaher corporation
23.3.9.1. Overview
23.3.9.2. Product Portfolio
23.3.9.3. Sales Footprint
23.3.9.4. Key Financials
23.3.9.5. SWOT Analysis
23.3.9.6. Strategy Overview
23.3.9.6.1. Marketing Strategy
23.3.9.6.2. Product Strategy
23.3.9.6.3. Channel Strategy
23.3.10. Agilent Technologies
23.3.10.1. Overview
23.3.10.2. Product Portfolio
23.3.10.3. Sales Footprint
23.3.10.4. Key Financials
23.3.10.5. SWOT Analysis
23.3.10.6. Strategy Overview
23.3.10.6.1. Marketing Strategy
23.3.10.6.2. Product Strategy
23.3.10.6.3. Channel Strategy
23.3.11. Perkin Elmer (Nexcelom Bioscience LLC.)
23.3.11.1. Overview
23.3.11.2. Product Portfolio
23.3.11.3. Sales Footprint
23.3.11.4. Key Financials
23.3.11.5. SWOT Analysis
23.3.11.6. Strategy Overview
23.3.11.6.1. Marketing Strategy
23.3.11.6.2. Product Strategy
23.3.11.6.3. Channel Strategy
23.3.12. F. Hoffmann-La Roche AG
23.3.12.1. Overview
23.3.12.2. Product Portfolio
23.3.12.3. Sales Footprint
23.3.12.4. Key Financials
23.3.12.5. SWOT Analysis
23.3.12.6. Strategy Overview
23.3.12.6.1. Marketing Strategy
23.3.12.6.2. Product Strategy
23.3.12.6.3. Channel Strategy
23.3.13. SHIMADZU CORPORATION
23.3.13.1. Overview
23.3.13.2. Product Portfolio
23.3.13.3. Sales Footprint
23.3.13.4. Key Financials
23.3.13.5. SWOT Analysis
23.3.13.6. Strategy Overview
23.3.13.6.1. Marketing Strategy
23.3.13.6.2. Product Strategy
23.3.13.6.3. Channel Strategy
23.3.14. Bio-Rad Laboratories
23.3.14.1. Overview
23.3.14.2. Product Portfolio
23.3.14.3. Sales Footprint
23.3.14.4. Key Financials
23.3.14.5. SWOT Analysis
23.3.14.6. Strategy Overview
23.3.14.6.1. Marketing Strategy
23.3.14.6.2. Product Strategy
23.3.14.6.3. Channel Strategy
23.3.15. Miltenyi Biotec
23.3.15.1. Overview
23.3.15.2. Product Portfolio
23.3.15.3. Sales Footprint
23.3.15.4. Key Financials
23.3.15.5. SWOT Analysis
23.3.15.6. Strategy Overview
23.3.15.6.1. Marketing Strategy
23.3.15.6.2. Product Strategy
23.3.15.6.3. Channel Strategy
23.3.16. Sinfonia Technology
23.3.16.1. Overview
23.3.16.2. Product Portfolio
23.3.16.3. Sales Footprint
23.3.16.4. Key Financials
23.3.16.5. SWOT Analysis
23.3.16.6. Strategy Overview
23.3.16.6.1. Marketing Strategy
23.3.16.6.2. Product Strategy
23.3.16.6.3. Channel Strategy
23.3.17. SHIBUYA CORPORATION
23.3.17.1. Overview
23.3.17.2. Product Portfolio
23.3.17.3. Sales Footprint
23.3.17.4. Key Financials
23.3.17.5. SWOT Analysis
23.3.17.6. Strategy Overview
23.3.17.6.1. Marketing Strategy
23.3.17.6.2. Product Strategy
23.3.17.6.3. Channel Strategy
23.3.18. Advanced Instruments
23.3.18.1. Overview
23.3.18.2. Product Portfolio
23.3.18.3. Sales Footprint
23.3.18.4. Key Financials
23.3.18.5. SWOT Analysis
23.3.18.6. Strategy Overview
23.3.18.6.1. Marketing Strategy
23.3.18.6.2. Product Strategy
23.3.18.6.3. Channel Strategy
23.3.19. Cell Culture Company, LLC
23.3.19.1. Overview
23.3.19.2. Product Portfolio
23.3.19.3. Sales Footprint
23.3.19.4. Key Financials
23.3.19.5. SWOT Analysis
23.3.19.6. Strategy Overview
23.3.19.6.1. Marketing Strategy
23.3.19.6.2. Product Strategy
23.3.19.6.3. Channel Strategy
23.3.20. BD
23.3.20.1. Overview
23.3.20.2. Product Portfolio
23.3.20.3. Sales Footprint
23.3.20.4. Key Financials
23.3.20.5. SWOT Analysis
23.3.20.6. Strategy Overview
23.3.20.6.1. Marketing Strategy
23.3.20.6.2. Product Strategy
23.3.20.6.3. Channel Strategy
23.3.21. Hamilton Company
23.3.21.1. Overview
23.3.21.2. Product Portfolio
23.3.21.3. Sales Footprint
23.3.21.4. Key Financials
23.3.21.5. SWOT Analysis
23.3.21.6. Strategy Overview
23.3.21.6.1. Marketing Strategy
23.3.21.6.2. Product Strategy
23.3.21.6.3. Channel Strategy
24. Assumptions and Acronyms Used
25. Research Methodology
Explore Healthcare Insights
View Reports
Automated Cell Biology Systems Market
